August 24, 2020 Update: The U.S. Food and Drug Administration issued an Emergency Use Authorization on August 23, 2020 for emergency use of convalescent plasma for the treatment of hospitalized patients with severe COVID-19. A clinical trial testing the investigational use of convalescent plasma for COVID-19 is closed to participant enrollment at Sutter.
Paying it Forward: Offering COVID-19 Survivor-Donated Blood Plasma to Patients
The FDA granted emergency authorization for convalescent plasma to treat hospitalized COVID-19 patients, closing Sutter's related clinical trial.
